Poonglim Pharmatech, 20% increase in vaccine production by applying minimum injection residual quantity technology
–
[중소벤처기업부 제공. 재판매 및 DB 금지]
–
(Gunsan = Yonhap News) Reporter Baek Do-in = A syringe for a novel coronavirus infection (Corona 19) vaccine produced by a Korean small and medium-sized business is expected to gain momentum in exports with the approval of the US Food and Drug Administration (FDA).
On the 17th, Poonglim Pharmatech, a medical device manufacturer in Gunsan, Jeollabuk-do, announced on the 17th that “A syringe for a Corona 19 vaccine to which LDS technology is applied has received US FDA approval.”
Earlier, Poonglim Pharmatech obtained an approval for use in Korea from the Ministry of Food and Drug Safety for this syringe, and then submitted an urgent use approval request to the US FDA last month.
Poonglim Pharmatech’s syringe passed the performance test for the minimum injection residual amount of a US pharmaceutical company, and also met the performance requirements.
This syringe can be injected more than 6 times per bottle, unlike regular syringes that can inject up to 5 times per bottle of Corona 19 vaccine. It is effective in increasing the production of the Corona 19 vaccine by an additional 20% by significantly reducing the loss of the remaining injection amount.
Poonglim Pharmatech has established a smart factory mass production system capable of producing more than 10 million syringes per month.
Poonglim Pharmatech has applied for domestic technology and design patents and is also applying for international patents in the United States and the European Union.
<저작권자(c) 연합뉴스,
Unauthorized reproduction-redistribution prohibited>
2021/02/17 12:25 sent
–
